and collude to suppress antidepressants that arepro-sexual. In June 2015, the advisory committee to the FDA voted to approve flibanserin; a product license followed in August. A more serious risk from taking SSRIs is irreversible post-SSRI sexual dysfunction (PSSD). The effects of PSSD are ...
and collude to suppress antidepressants that arepro-sexual. In June 2015, the advisory committee to the FDA voted to approve flibanserin; a product license followed in August. A more serious risk from taking SSRIs is irreversible post-SSRI sexual dysfunction (PSSD). The effects of PSSD are ...
Apaper publishedin the BMJ found thatexercise was moderately effective at treating depression compared to existing treatmentswhen used alone or in combination with other established therapies. Moreover, the benefits from exercise “tended to be proportional to the intensity prescribed,” meaning more vig...
Traditional antidepressants largely interfere with monoaminergic transport or degradation systems, taking several weeks to have their therapeutic actions. Moreover, a large proportion of depressed patients are resistant to these therapies. Several atypic
Jang et al noted that Asians of Chinese descent tend to follow Confucian ethics, which state that "self-concealment of emotional trouble is a virtue".3 Therefore, patients tend to tolerate the disease internally and suppress their emotions, instead of seeking treatment. In our study, it was ...
and collude to suppress antidepressants that arepro-sexual. In June 2015, the advisory committee to the FDA voted to approve flibanserin; a product license followed in August. A more serious risk from taking SSRIs is irreversible post-SSRI sexual dysfunction (PSSD). The effects of PSSD are ...
A whole-cell voltage clamp confirmed YY-23 as a selective allosteric inhibitor of the GluN1-GluN2D subtype, which acts to suppress GABAergic neurons. Its inhibitory effect comes from binding to the S2 segment of the ligand-binding domain of the GluN2D subunit. The discovery of YY-23 ...